CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 436 enrolled
Drug / intervention
GK530Gdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01910064
NCT01910064Phase 3Completed
CompareCT.gov

A Long Term Study of GK530G in Subjects With Acne Vulgaris

Galderma R&D·interventional·Posted Jul 29, 2013·Updated Mar 28, 2017

In Brief

A Phase 3 clinical trial evaluating GK530G for Acne Vulgaris. Completed, enrolled 436 participants across 16 sites.

Detailed Summary

This open label study is to determine the safety profile of GK530G in a long-term treatment (up to 12 months) in subjects with acne vulgaris and to evaluate the efficacy of GK530G in a long-term treatment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcne Vulgaris
CountriesJapan
Collaborators--

Timeline

Phase 3CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedJul 29, 2013
Enrollment StartMay 1, 2013
Primary CompletionAug 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 12.9 years ago

Interventions

GK530Gdrug